Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.87 USD | +5.35% | -0.25% | -28.58% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.58% | 2B | |
+1.61% | 42.75B | |
+47.70% | 41.61B | |
+12.07% | 41.34B | |
-8.83% | 26.59B | |
+6.89% | 25.49B | |
-23.36% | 18.12B | |
+30.01% | 12.24B | |
-2.42% | 11.76B | |
+8.06% | 11B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics Says Investigational Hereditary Angioedema Treatment Shows Promise in Phase 1 Study